Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department is aware of Blenrep; and when it will be available to NHS patients.

The Department is aware of the medicine belantamab mafodotin (Blenrep). In the United Kingdom, medicines need to have a licence before they can be marketed, granted by the Medicines and Healthcare products Regulatory Agency (MHRA). Licences confirm the health condition the medicine should be used for and the recommended dosage. To get a licence, the manufacturer of the medicine is required to provide evidence that shows that the medicine is safe and effective enough to be used for a specific condition and for a specific group of patients, and that they can manufacture the medicine to the required quality.

After a review of the safety, quality, and efficacy of Blenrep, it was approved for a marketing authorisation on 17 April, in combination with other products for use in the treatment of adult patients with multiple myeloma.

Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on new medicines represent a clinically and cost-effective use of resources. Following receipt of the marketing authorisation, the NICE will progress its appraisals of Blenrep as soon as possible.